1. LPRO reported a $144.4 million net loss in Q4 2024. 2. Board changes include Jessica Buss as CEO and Michelle Glasl as COO. 3. Certified loans fell to 26,065 in Q4 compared to 26,263 a year prior. 4. Total revenue for 2024 dropped to $24 million from $117.5 million in 2023. 5. Profit share revenue forecast was adjusted downward by $81.3 million.

1. Nutex Health's revenue soared 93.8% to $479.9 million in 2024. 2. Net income was $52.2 million, reversing a loss from 2023. 3. Arbitration contributed significantly, adding $169.7 million to revenue. 4. Adjusted EBITDA increased over 1,000% year-on-year to $123.7 million. 5. Company sees continued operational improvements and revenue growth.

1. MySize's revenue increased 18% to $8.26 million year-over-year. 2. Net loss decreased by 37%, showcasing improved financial health. 3. Cash reserves more than doubled, indicating stronger liquidity. 4. Over 100 brands adopted MySize's AI sizing solutions, enhancing market reach. 5. Significant tech integrations support e-commerce expansions and client retention.

1. FDA approves VYKAT XR for treating hyperphagia in Prader-Willi syndrome. 2. VYKAT XR is set to launch in the U.S. in April 2025. 3. Approval represents a major milestone for Soleno and PWS patients. 4. VYKAT XR was based on a successful Phase 3 clinical trial. 5. Soleno launched a patient support program for VYKAT XR access.

1. GORV faced challenges in revenue, reporting $159.9 million in Q4 2024. 2. Net loss is $96.1 million for Q4 2024, improved from $108 million in Q4 2023. 3. The company plans to divest three store locations to strengthen its balance sheet. 4. Annual revenue fell to $871.6 million, down from $1,082.7 million in 2023. 5. Adjustments included significant impairment charges affecting liquidity and operations.

1. Revenue increased 23.9% to $379.8 million in FY 2024. 2. Q4 2024 gross margin rose to 36.6%, up from 22.0% in Q4 2023. 3. Company backlog grew to $401.3 million, indicating strong future demand. 4. Huzhou Phase 3.2 expansion expected to meet rising customer demand by Q4 2025. 5. 2025 revenue guidance targets $450 million to $475 million, reflecting sustained growth.

1. Petco's Q4 revenue fell 7.3%, but comparable sales rose 0.5%. 2. Gross profit decreased 2.8%, with adjusted EBITDA at $96.1 million. 3. Net loss for 2024 sharply decreased, showing improvement over previous year. 4. Guidance for FY2025 projects slight decline in revenue with improved EBITDA. 5. Leadership expresses confidence in achieving double-digit EBITDA growth by 2025.

1. Glucotrack advanced to clinical stage with CBGM technology. 2. Secured $16.3 million in funding for development milestones. 3. Leadership team strengthened with key appointments in 2024. 4. CBGM expected to receive FDA IDE approval by Q4 2025. 5. Promising results from initial human clinical study reported.

1. Cloudastructure's revenue rose 125% to $1.4 million in 2024. 2. New customers increased by 30%, showcasing broad-based sales growth. 3. Remote guarding revenue surged by 404%, highlighting heightened security needs. 4. The company expanded contracts with major multifamily investment firms. 5. Direct listing on Nasdaq enhances visibility and liquidity for shareholders.

1. Phase 1/2 data shows tumor shrinkage in resistant tumor patients. 2. Solnerstotug demonstrates well-tolerated safety profile in trials. 3. Target enrollment completed; full data anticipated by end of 2025. 4. Financial position supports operations through Q2 2026. 5. 2024 loss decreased compared to previous year, indicating improved management.